Intravenous Tranexamic Acid

ConditionsObese Patients Obese Patients With Bariatric Surgery Bleeding

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-60

SponsorAin Shams University

About this trial

Tranexamic acid is a promising option for minimizing blood loss in high-risk bariatric surgery patients, particularly in those with obesity, diabetes, and other comorbidities. When used appropriately, TXA can reduce the need for blood transfusions, maintain hemodynamic stability, and lower the incidence of complications related to blood loss.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

High-risk patients, with obesity, BMI more than 45,

Patients with Preexisting cardiovascular condition, Hypertension, diabetes, or coagulation disorders, thyroid dysfunction and pulmonary disorders.

Disqualifiers

patients with active thromboembolic disorders.

Patients with preexisting renal dysfunction,

Trial design

Design model

Parallel

Treatments tested in this trial

After induction of anaesthesia tranexamic acid will be administered at the start of surgery to reduce intraoperative bleeding. loading dose of 10 mg/kg for high BMI patients who are undergoing bariatr
Drug
This intervention will be applied for High-risk patients, with obesity, BMI more than 45, Preexisting cardiovascular condition, Hypertension, diabetes, or coagulation disorders, thyroid dysfunction and pulmonary disorders.

Treatment groups

128 Participants

are divided into 2 treatment groups

Group A: tranexamic groupActive comparator 1 intervention

Group B: control groupNo intervention 0 interventions

Trial outcomes

Primary outcomes

Intraoperative blood Loss

Intraoperative and postoperative Blood Loss will be calculated in the suction and wet gauzes by blood and the need for blood transfusion will be recorded

Time frame

"Perioperative"

Secondary outcomes

postoperative risk of thromboembolism, infections, delayed wound healing, or longer hospital stays

The patients will be followed up for one week for possible incidence of side effects

Time frame

pre-intervention/surgery""Postoperative "up to 1 week"

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Ain Shams University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: